Intro

Systemic amyloidosis from transthyretin (ATTR) protein is increasingly recognized as an important cause of heart failure in older people. JAMA Deputy Editor Mary McGrae McDermott, MD, discusses the diagnosis and treatment of ATTR protein cardiomyopathy with Frederick L. Ruberg, MD, of the Boston University Chobanian & Avedisian School of Medicine. Related Content:

• Cardiac Amyloidosis Due to Transthyretin Protein